Gram-negative sepsis treatment containing hemoglobin-modified body as an active ingredient

• 1. 用于癌症靶向治疗和诊断成像的包含基于修饰的血红蛋白的治疗剂的药物组合物 [P] . 中国专利： CN105407911B . 2020.05.12
• 2. 用于癌症靶向治疗和诊断成像的包含基于修饰的血红蛋白的治疗剂的药物组合物 [P] . 中国专利： CN105407911A . 2016-03-16
• 3. Gram-negative sepsis treatment containing hemoglobin-modified body as an active ingredient [P] . 韩国专利： KR19980020773A . 1998-06-25

  机译： 以血红蛋白修饰体为有效成分的革兰氏阴性脓毒症治疗

• 4. The use of body its own fibroblasts and epidermal cells, as the active ingredient, - tray for use in the intracorporeal treatment and as active ingredient mediator for the locally treatment [P] . 德国专利： DE3837669A1 . 1989-06-01

  机译： 使用身体自身的成纤维细胞和表皮细胞作为活性成分-用于体内治疗的托盘和作为局部治疗的活性成分介质

• 5. Preventive agent for gram-negative bacterial infections and gram-negative bacterial infections containing guazinomin as an active ingredient [P] . JP2021195343A . 2021-12-27

  机译： 革兰氏阴性细菌感染的预防剂和含有国嗪胺作为活性成分的革兰氏阴性细菌感染

• 1. Feasibility study of cyclodextrins as active pharmaceutical ingredients for the treatment of GM1-gangliosidosis [J] . Yuki Maeda, Keiichi Motoyama, Taishi Higashi, 亚洲药物制剂科学(英文) . 2016,第001期
• 2. Flowable Seed Treatments: A New Polymeric Dispersing System to Increase Active Ingredient Content and to Improve Flowable Seed Formulation Performance and Flexibility [C] . Rocco Di Modugno, Federico De Pellegrini, Brad Eidem, Symposium on pesticide formulation and delivery systems . 2016
• 3. Comparison of two human cell lines following exposure to low dose radiation and treatment with soybean miso and its active ingredient genistein. [D] . Sattler, Jennifer A. 2013
• 4. A Thrombomodulin Mutation that Impairs Active Protein C Generation Is Detrimental in Severe Pneumonia-Derived Gram-Negative Sepsis (Melioidosis) [O] . Liesbeth M. Kager, W. Joost Wiersinga, Joris J. T. H. Roelofs, 2014
• 5. A thrombomodulin mutation that impairs active protein C generation is detrimental in severe pneumonia-derived gram-negative sepsis (melioidosis). [O] . Liesbeth M Kager, W Joost Wiersinga, Joris J T H Roelofs, 2014

• 1. BACKGROUND： Vibrio vulnifi cus inside the body could activate the NF-!B signaling pathwayand initiate the inflammatory cascade. The lung is one of the earliest organs affected by sepsisassociated with acute lung injury. High mobility group protein B1 （HMGB1） is an important late-actingpro-infl ammatory cytokine involving in the pathophysiology of sepsis. It is also involved in the injuryprocess in the lung, liver and intestine. There has been no report on the involvement of HMGB1 inVibrio vulnifi cus sepsis-induced lung injury.METHODS： Sixty rats were randomly divided into a normal control group （group A, n=10） anda Vibrio vulnificus sepsis group （group B, n=50）. Sepsis was induced in the rats by subcutaneousinjection of Vibrio vulnificus （concentration 6×108 cfu/mL, volume 0.1 mL/100g）） into the left lowerlimbs. The rats in group B were sacrifi ced separately 1, 6, 12, 24, and 48 hours after the infection.Their lungs were stored as specimens, lung water content was measured, and lung pathology wasobserved under a light microscope. The expressions of the HMGB1 gene and protein in the lungswere detected by RT-PCR and Western blot. Data were analyzed with one-way analysis of variance（ANOVA） and the LSD method for pair-wise comparison between the two groups. P〈0.05 wasconsidered statistically signifi cant.RESULTS： Compared to group A （0.652±0.177）, HMGB1 mRNA expression in the lungs ofgroup B was signifi cantly higher at 0 hour （1.161±0.358, P=0.013）, 24 hours （1.679±0.235, P=0.000）,and 48 hours （1.258±0.274, P=0.004） （P〈0.05）, and peaked at 24 hours. Compared to group A（0.594±0.190）, HMGB1 protein expression at 6 hours （1.408±0.567, P=0.026） after infection wassignificantly increased （P〈0. 05）, and peaked at 24 hours （2.415±1.064, P=0.000） after infection.Compared to group A （0.699±0.054）, lung water content was significantly increased at 6 hours（0.759±0.030, P=0.001）,12 hours （0.767±0.023, P=0.000）, 24 hours （0.771±0.043, P=0.000） and 48hours （0.789±0.137, P=0.000） after infection （P〈0.05）. Compared to group A, pathological changesat 12 hours in group B indicate marked pulmonary vascular congestion, interstitial edema andinfl ammatory infi ltration. Alveolar cavity collapse and boundaries of the alveolar septum could not beclearly identifi ed.CONCLUSION： Vibrio vulnifi cus sepsis can lead to injury in rat lungs, and increased HMGB1expression in lung tissue may be one of the mechanisms for injury from Vibrio vulnifi cus sepsis. [J] . Qiao-meng Qiu ,Zhong-wang Li ,Lu-ming Tang . 世界急诊医学杂志(英文) . 2011,第4期
• 2. A network pharmacology approach to determine the active ingredients and potential targets of Chinese herb Juglans mandshurica Maxim. for treatment of lung cancer [J] . Yeqing Du1 ,Qiang Ren1 ,Zhiyang Yan1 . 亚洲传统医药 . 2019,第001期
• 3. Treatment with plasmapheresis, immunoglobulins and rituximab for chronic-active antibody-mediated rejection in kidney transplantation: Clinical, immunological and pathological results [J] . Alberto Mella ,Ester Gallo ,Maria Messina . 世界移植杂志 . 2018,第5期
• 4. Observational Study of a Multi-Active Ingredient Over-the-Counter Cold Remedy Following Active Pharmacist Recommendation [J] . Gillian Lisa Phillipson ,John David Hull ,Boleslaw Samoliński . 呼吸病期刊（英文） . 2017,第1期
• 5. 实验建议:一种血红蛋白类氧载体的新修饰方式:带负电荷的血红蛋白 [C] . 许铁 ,燕宪亮 ,刘大跃 . 第13届全国实验血液学会议 . 2011
• 6. 脓毒症治疗中联合检测降钙素原、D-二聚体、乳酸的价值 [A] . 宁超 . 2019